Parabilis (PBLS) director-linked LLC makes open-market buy of 12,500 shares

Filing Impact

(Moderate)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Parabilis Medicines, Inc. director-associated entity Apothecary Capital LLC made an open-market purchase of 12,500 shares of common stock at $20.00 per share on June 11, 2026. The shares are held indirectly, with Alan Sebulsky disclaiming beneficial ownership except for any pecuniary interest.

Insider Trade Summary

Net Buyer: 12,500 shares ($250,000)

Net Buy 1 txn

Insider SEBULSKY ALAN

Role null

Bought 12,500 shs ($250K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,500	$20.00	$250K

Holdings After Transaction: Common Stock — 12,500 shares (Indirect, By Apothecary Capital LLC)

Footnotes (1)

[object Object]

Key Figures

Shares purchased: 12,500 shares Purchase price: $20.00 per share Shares held after trade: 12,500 shares +3 more

6 metrics

Shares purchased 12,500 shares Open-market purchase of common stock on June 11, 2026

Purchase price $20.00 per share Price for non-derivative common stock transaction

Shares held after trade 12,500 shares Indirect holdings by Apothecary Capital LLC following transaction

Transaction code P (purchase) Non-derivative open-market or private transaction

Ownership type Indirect (I) Held by Apothecary Capital LLC, associated with Alan Sebulsky

Net buy direction Net-buy of 12,500 shares Transaction summary shows net-buy direction

Key Terms

open-market purchase, indirect ownership, pecuniary interest, Section 16

4 terms

open-market purchase financial

"The Form 4 shows an open-market acquisition of 12,500 shares of Parabilis Medicines common stock at $20.00 per share"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"The transaction was reported as an indirect holding through Apothecary Capital LLC associated with director Alan Sebulsky"

pecuniary interest financial

"except to the extent of his pecuniary interest therein, if any"

Section 16 regulatory

"The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 05:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SEBULSKY ALAN

(Last)

(First)

(Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE

MASSACHUSETTS

02140

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/11/2026		P		12,500	A	$20	12,500	I	By Apothecary Capital LLC⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares held by Apothecary Capital LLC ("Apothecary Capital"). The Reporting Person is the managing member of Apothecary Capital and may be deemed to share voting, investment and dispositive power with respect to the securities held by Apothecary Capital. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

	/s/ Teresa Jurgensen, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Parabilis Medicines (PBLS) report in this Form 4?

Parabilis Medicines reported an open-market purchase of 12,500 shares of common stock at $20.00 per share. The transaction was reported as an indirect holding through Apothecary Capital LLC associated with director Alan Sebulsky.

Who effectively acquired Parabilis Medicines (PBLS) shares in this filing?

Apothecary Capital LLC acquired the 12,500 Parabilis Medicines shares. Director Alan Sebulsky is the managing member and may share voting and investment power but disclaims beneficial ownership beyond any pecuniary interest described in the Form 4 footnote.

Was the Parabilis Medicines (PBLS) insider trade a purchase or a sale?

The reported insider trade was a purchase. The Form 4 shows an open-market acquisition of 12,500 shares of Parabilis Medicines common stock at $20.00 per share, categorized as a non-derivative transaction and coded as a purchase (P).

How many Parabilis Medicines (PBLS) shares does the reporting entity hold after this trade?

After the transaction, Apothecary Capital LLC is shown holding 12,500 shares of Parabilis Medicines common stock indirectly. This post-transaction figure matches the number of shares purchased in the reported open-market transaction on June 11, 2026.

How is Alan Sebulsky’s ownership in Parabilis Medicines (PBLS) characterized?

Alan Sebulsky is the managing member of Apothecary Capital LLC and may share voting and investment power. However, he disclaims beneficial ownership of the LLC-held shares for Section 16 purposes, except to the extent of any pecuniary interest described.